Adarza News

Biosensing firm Adarza BioSystems is getting ready to launch its Ziva protein detection platform, though a little later than originally expected and including a new application.

In February, the firm raised $25 million in Series D funding and planned a summer release of its platform. But like many other companies, Adarza found itself having to shift its strategy as the SARS-CoV-2 pandemic shut down non-essential businesses across the economy. Instead of launching the system with its planned focus on immuno-oncology and neurology, the firm has moved to use its technology for immune profiling research supporting work like SARS-CoV-2 vaccine development.

Biosensing firm Adarza BioSystems is getting ready to launch its Ziva protein detection platform, though a little later than originally expected and including a new application.

In February, the firm raised $25 million in Series D funding and planned a summer release of its platform. But like many other companies, Adarza found itself having to shift its strategy as the SARS-CoV-2 pandemic shut down non-essential businesses across the economy. Instead of launching the system with its planned focus on immuno-oncology and neurology, the firm has moved to use its technology for immune profiling research supporting work like SARS-CoV-2 vaccine development.